NGNE
Neurogene Inc

352
Mkt Cap
$291.21M
Volume
152,405.00
52W High
$37.27
52W Low
$6.88
PE Ratio
-4.08
NGNE Fundamentals
Price
$18.06
Prev Close
$18.80
Open
$18.85
50D MA
$21.44
Beta
1.48
Avg. Volume
195,626.36
EPS (Annual)
-$4.28
P/B
1.00
Rev/Employee
$8,644.86
Loading...
Loading...
News
all
press releases
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today provided an update on...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company...
Business Wire·11d ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of "Hold" from Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been given an average rating of "Hold" by the seven ratings firms that are currently covering the company, MarketBeat.com reports. One...
MarketBeat·22d ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of "Hold" from Brokerages
Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received an average recommendation of "Hold" from the seven brokerages that are covering the company, MarketBeat.com reports. One analyst has rated...
MarketBeat·22d ago
News Placeholder
Neurogene (NASDAQ:NGNE) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Neurogene from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·1mo ago
News Placeholder
Neurogene Inc. (NASDAQ:NGNE) Given Average Rating of "Hold" by Brokerages
Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned an average recommendation of "Hold" from the seven analysts that are covering the firm, MarketBeat Ratings reports. One...
MarketBeat·2mo ago
News Placeholder
FY2025 EPS Estimates for Neurogene Increased by Analyst
Neurogene Inc. (NASDAQ:NGNE - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Neurogene in a report released on Monday, November 17th. HC Wainwright analyst M...
MarketBeat·2mo ago
News Placeholder
Leerink Partnrs Forecasts Stronger Earnings for Neurogene
Neurogene Inc. (NASDAQ:NGNE - Free Report) - Research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for shares of Neurogene in a report released on Wednesday...
MarketBeat·2mo ago
News Placeholder
Neurogene (NASDAQ:NGNE) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Neurogene from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Neurogene (NASDAQ:NGNE) Issues Quarterly Earnings Results
Neurogene (NASDAQ:NGNE - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·2mo ago
<
1
2
...
>

Latest NGNE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.